Navigation Links
StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
Date:10/17/2007

FRAMINGHAM, Mass., Oct. 17 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) today reported receipt of a $500,000 strategic investment from Inverness Medical Innovations, Inc. (Amex: IMA). In connection with this financing, StatSure and Inverness signed two additional agreements. First, the two companies signed an agreement whereby Inverness acquired an option to the exclusive, worldwide marketing and distribution rights to certain infectious disease diagnostic tests developed by StatSure that may utilize specified Inverness and/or StatSure intellectual property. If exercised by Inverness, the option provides for StatSure and Inverness to equally share development expenses and profits. StatSure and Inverness also entered into a license agreement whereby Inverness granted to StatSure a license to certain Inverness lateral flow patents for use in a rapid test to detect HIV antibodies in point-of-care markets subject to payment of royalties to Inverness. This license pertains to HIV tests using formats other than the StatSure's "barrel format" which is already being sold by Inverness and awaiting a CLIA Waiver from the FDA.

The strategic investment consists of a purchase of 1,428,572 common shares at a price of 35 cents per share. Additionally, Inverness received 5 year warrants to purchase up to an additional 1.1 million shares of the Company's stock at a price of 75 cents per share. The proceeds of this investment will be used for general corporate purposes and to fund development of other infectious disease applications for the Company's patented test format.

Steve Peltzman, StatSure's CEO and Chairman, stated: "We are delighted with the opportunity to broaden and streng
'/>"/>

SOURCE StatSure Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
2. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
3. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
4. First Study To Show Positive Benefit On Atherosclerosis For People With Early Signs Of Diseased Arteries
5. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
6. Materia Licenses Metathesis Catalyst Platform to Eisai
7. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
8. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2008)...ewswire-FirstCall/ --,Pharmaceutical company Pharm... the Phase 3 clinical trial evaluating the long te...tasis has concluded with no serious,adverse events...atment., A total of 123 subjects started treatmen...ects completed the full 12 months of the trial. Of...
(Date:8/19/2008)...- Particle Sciences Inc. has,expanded its Combinat...d,pilot production capabilities with the installat...ing line. The core of the pilot line,comprising a...20T injection,molder, enables the production of hi...ition gives Particle Sciences the ability to go fr...
(Date:8/19/2008)...used to identify molecular,signature of motor neur...-USNewswire/ -- ALS Therapy,Development Institute ...LS,biomarker effort using blood samples collected ...ps. These ongoing projects are part of the,Institu...ression of genes,and proteins, at the onset of, an...
(Date:8/19/2008)...ll/ -- Vical Incorporated,(Nasdaq: VICL ) today a...ska,Institute, a leading European medical universi...se Control (SMI), a governmental expert agency, to...iojector(R) 2000,needle-free injection system (Bio...multivalent preventive DNA vaccine against HIV., ...
Breaking Medicine Technology:12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3Particle Sciences Expands Its Combination Product Capabilities 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Many States Still Fall Short in Emergency Preparedness 3A Report 8484 1Many States Still Fall Short in Emergency Preparedness 3A Report 8484 2Many States Still Fall Short in Emergency Preparedness 3A Report 8484 3Many States Still Fall Short in Emergency Preparedness 3A Report 8484 4Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 2SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 1SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 2
...ce shortly, CARMIEL, Israel, April 18, 2007 /PRNew.... today announced that it has received,written not...ation,(FDA) that it may initiate a Phase III clini... candidate, prGCD, a proprietary plant,cell expres...GCD),for the treatment of Gaucher Disease, a lyso...
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
... of Missouri birth statistics by researchers at Wa...s appearing// in the February issue of the America... African-American women are three times more likel...rematurely than Caucasian women. In addition, th...
..., a clinical assistant professor in Indiana Univer...ience//, has offered some tips to help parents of ...enage children. Teenage is the most difficult pha...and romance form an integral part of this mind-bog...
...ancer-fighting film that could be applied directly... can be made into any size and shape, is capable o... site as it dissolves over several weeks. This eff...bypass administering conventional chemotherapy tre...
...succumbed to the flu, in British Columbia//. The...ly peaks in the months of December and January. Th...ters, say experts. According to Dr. Theresa Tam o...gency of Canada, in an average year, about 4,000 C...
Other Medicine News:Health News:African-American Mothers More Likely to Deliver Prematurely 2Health News:A Better Way to Deliver Cancer Drugs 2Health News:Flu Strikes Late - Child Succumbs 2
...e (GH) is a monomeric protein produced and stored ...H is released from the pituitary into the bloodstr...trol of hypothalamic somatostatin (SS) and GH-rele...of GH release appears to be regulated by somatosta...
...he most potent glucocorticoid produced by the huma...d with high affinity to corticosteroid-binding glo...lbumin. Cortisol acts on specific intracellular re...ms, including immune function, glucose counter-reg...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
Medicine Products: